The phase 3 SURMOUNT programme assessed the safety and efficacy of tirzepatide as obesity treatment and the medication has now been approved (November 2023) for chronic weight management by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) [46, 47]
This guide explains how GLP-1 pills and shots compare, what research says about muscle loss, and what doctors recommend to protect strength during treatment
GLP-1 drugs improve blood sugar control by: Enhancing insulin secretion only when glucose is high lower risk of hypoglycemia Reducing post-meal glucose spikes Supporting beta-cell function Why They Cause Weight Loss
Patients should inspect potential injection sites before each dose, avoiding areas with existing redness, bruising, scarring, or skin abnormalities
Analizziamo dati e mercato per guidare la crescita del tuo business
Potential risks may include: Overdosing, which may lead to symptoms such as nausea, vomiting, or other adverse effects